Pomaglumetad Effects on Glutamate Biomarkers
Biomarker Assessment of Pomaglumetad on Glutamate Targets: Proof of Clinical Mechanism of Action (POCM)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama, Birmingham
-
-
California
-
Los Angeles, California, United States, 90095
- University of California, Los Angeles
-
-
New York
-
New York, New York, United States, 10032
- Columbia University
-
New York, New York, United States, 10016
- New York University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Medically healthy
- Capable of understanding the study procedures and able to provide informed consent
- Men and women must agree to use a reliable method of birth control during the study. Women who are post-menopausal or otherwise not of childbearing potential are also eligible
Exclusion Criteria:
- Current or past Axis I psychiatric history
- Positive urine toxicology
- History of recreational ketamine use, recreational PCP use, or an adverse reaction to ketamine. Subjects who have participated in prior research ketamine studies will be eligible. Subjects can have infusions not more frequently than biweekly, and not more than 1/month on average, therefore subjects entering the study will need to wait one month if they had a single infusion and 6 weeks if they have had two closely spaced infusions.
- History of first-degree relative with schizophrenia
- History of violence
- Presence or positive history of significant medical illness
- Presence or positive history neurological illness or any other disease/procedure/accident/intervention association with significant injury to or malfunction of the central nervous system (CNS) or history of significant head injury
- Pregnancy or breast feeding
- Metal implants, pacemaker, other metal or paramagnetic objects contained within the body
- Medicinal patch, unless removed prior to MRI scan
- Currently taking any psychotropic medication, including antidepressant medications, benzodiazepines, antipsychotic medications, mood stabilizers, anti-epileptic medications and stimulants.
- Claustrophobia
- Suicidal ideation with intent or plan in the 6 months prior to screening
- Weight > 86.95 kg (191.2 lbs)
- Subthreshold pharmacoBOLD response during screening ketamine infusion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: POMA 40 mg BID
40 mg BID for 10 days
|
Pomaglumetad ("POMA") is a mGluR 2/3 partial agonist
Other Names:
|
|
Experimental: POMA 160 mg BID
160 mg BID for 10 days
|
Pomaglumetad ("POMA") is a mGluR 2/3 partial agonist
Other Names:
|
|
Placebo Comparator: Placebo
Placebo BID for 10 days
|
matching placebo tablets
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PharmacoBOLD change
Time Frame: Day 1 to Day 10
|
pharmacoBOLD change, as summarized by the Amplitude measure
|
Day 1 to Day 10
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Brief Psychiatric Rating Scale (BPRS)
Time Frame: Day 1 to Day 10
|
Clinical rating scale assessing common psychiatric symptoms
|
Day 1 to Day 10
|
|
Clinician Administered Dissociative States Scale (CADSS)
Time Frame: Day 1 to Day 10
|
Rates dissociative symptoms
|
Day 1 to Day 10
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Jeffrey A Lieberman, MD, New York State Psychiatric Institute
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 7285 (CTEP)
- 271201200007I-4-27100003-2 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.